In an increasingly unstable world, we are inspired by those who are seeking solutions to humanity’s most pressing problems.
Investment Stage: Seed
Portfolio 5
| Date | Name | Website | Total Raised | Location |
| 13.01.2026 | OutSee | outsee.co.uk | $5.82M | United Kin... |
| 23.09.2025 | Scindo | scindo.bio | $5.4M | United Kin... |
| 15.07.2025 | Aeon | aeon.life | $9.51M | Switzerlan... |
| 19.02.2024 | GlycanAge | glycanage.com | $12.9M | Croatia |
| 02.06.2023 | XONAI | xonai.io | $3.5M | United Kin... |
Mentions in press and media 19
| Date | Title | Description |
| 03.03.2026 | Antiverse: $9.3 Million Raised For AI-Driven Antibody Development Targeting Undruggable Disease Targets | Antiverse, an AI-driven techbio company specializing in de novo antibody design for challenging drug targets, has raised $9.3 million in Series A financing to accelerate the development of therapeutic antibodies aimed at historically undrug... |
| 14.01.2026 | OutSee Secures £2.5M, Propels AI Genomics for Drug Discovery | OutSee secured a significant £2.5M seed funding round. Ahren Innovation Capital spearheaded the investment. This capital fuels OutSee's groundbreaking AI-powered Nomaly platform. Nomaly uses a "genomics-first" approach. It predict... |
| 13.01.2026 | OutSee Closes £2.5M Seed Funding Round | OutSee, a Cambridge, England-based developer of an AI-based predictive genomics approach to target discovery, raised £2.5M in seed funding. The round was led by Ahren Innovation Capital, with participation from Kadmos Capital, Panacea, Empi... |
| 12.01.2026 | OutSee: £2.5 Million Seed Round Completed And Partnership With o2h Discovery | OutSee, an AI-enabled genomics and drug discovery company, has closed a £2.5 million seed funding round and signed a strategic agreement with o2h discovery to begin a collaborative drug discovery programme around OutSee’s lead drug target c... |
| 19.12.2025 | GlycanAge Secures Major Funding. Reshaping Healthcare with Biological Age Diagnostics. | GlycanAge, a UK biotech rooted in Croatian research, just secured €7.4 million. This significant investment propels glycan-based aging diagnostics into mainstream healthcare. Their "inflammaging" clock, a cutting-edge biomarker, p... |
| 18.12.2025 | UK longevity startup GlycanAge raises €7.4 million to bring glycan-based ageing diagnostics into mainstream healthcare | UK-based longevity startup GlycanAge has raised €7.4 million ($8.7 million) in fresh funding to accelerate the clinical development of its technology and expand access to glycan testing for clinicians worldwide. The round was led by Fifth Q... |
| 18.12.2025 | GlycanAge Founders on Boosting Transition From “Wellness” Biomarker to Hospital Diagnostic | Croatia, UK ~ Company: Glycans, sugar molecules that shape immune response, inflammation and ageing, are well studied in research labs but rarely used in everyday clinical diagnostics. Croatian-founded GlycanAge, a London-headquartered biot... |
| 27.09.2025 | Scindo Secures €4.5M to Ignite AI-Driven Sustainable Ingredient Revolution | Scindo, a UK-based biotech innovator, secured €4.5 million. This vital funding accelerates its advanced AI platform. The platform discovers and engineers next-generation enzymes. These bio-catalysts enable sustainable, bio-based ingredients... |
| 23.09.2025 | London’s Scindo raises €4.5 million to accelerate sustainable ingredients platform | Scindo, a UK-based startup developing a data-rich AI platform to discover and design next-generation enzymes, has raised €4.5 million in funding to enable bio-based ingredients and sustainable chemistry across multiple high-value sectors. T... |
| 15.07.2025 | “Es geht darum, etwas zu schaffen, das wirklich bleibt” | Das Zürcher HealthTech-Startup Aeon, 2023 von Tim Seithe, der zuvor bereits Tillhub aufgebaut und verkauft hat, sowie Samuel Frey gegründet, bietet “medizinisch validierte Gesundheits-Check-Ups, die KI, Ganzkörper-MRT, Blut- und Gendaten ko... |
Show more